Leading DNA vaccine discovery company, Inovio Biomedical Corporation announced that their Scientific Advisory Board Chairman, Dr. David B. Weiner, highlighted advances in the company’s leading electroporation-delivered SynCon™ DNA vaccines at the AIDS Vaccine 2009 Conference in Paris.

The study, led by Dr. Weiner’s team at the University of Pennsylvania, included collaborators from Inovio and Merck. The team previously reported that DNA vaccines delivered using electroporation induced dramatic increases in T-cell and antibody-based immune responses. This collaborative study was the first to directly compare a DNA plasmid-electroporation platform with a recombinant Ad5 vector in an SIV model in non-human primates.

Dr. Weiner presented pre-clinical data showing higher levels of immune responses induced by Inovio’s DNA vaccines than to those induced by the recombinant adenovirus serotype 5 (Ad5) vector. Historically, recombinant Ad5 vector has been shown to be one of the most potent viral vectors for vaccines.

In his presentation, Dr. Weiner also

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday October 20, 2009

DrStockPick.com Stock Report!

**************************************************************

UnitedHealth Group (NYSE:UNH) reported third quarter results today, including growth in revenues and net earnings and a continued strong financial position. Stephen J. Hemsley, president and chief executive officer of UnitedHealth Group, said, “We combined successful overall cost containment and strong execution in our services businesses to continue to perform during a difficult economic period. This reinforces the value of our diversified business model. We continue to focus on delivering value for customers and stakeholders through responsive, high